In last trading session, Coherus Biosciences Inc (NASDAQ:CHRS) saw 2.59 million shares changing hands with its beta currently measuring 0.91. Company’s recent per share price level of $0.79 trading at -$0.04 or -4.24% at ring of the bell on the day assigns it a market valuation of $91.60M. That closing price of CHRS’s stock is at a discount of -207.59% from its 52-week high price of $2.43 and is indicating a premium of 16.46% from its 52-week low price of $0.66. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.84 million shares which gives us an average trading volume of 1.85 million if we extend that period to 3-months.
For Coherus Biosciences Inc (CHRS), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.83. Splitting up the data highlights that, out of 5 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.28 in the current quarter.
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Upright in the red during last session for losing -4.24%, in the last five days CHRS remained trading in the red while hitting it’s week-highest on Monday, 05/12/25 when the stock touched $0.79 price level, adding 25.47% to its value on the day. Coherus Biosciences Inc’s shares saw a change of -42.75% in year-to-date performance and have moved -16.50% in past 5-day. Coherus Biosciences Inc (NASDAQ:CHRS) showed a performance of -18.93% in past 30-days. Number of shares sold short was 32.57 million shares which calculate 17.54 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 3.52 to the stock, which implies a rise of 77.59% to its current value. Analysts have been projecting 1.05 as a low price target for the stock while placing it at a high target of 6. It follows that stock’s current price would drop -32.91% in reaching the projected high whereas dropping to the targeted low would mean a loss of -32.91% for stock’s current value.
Coherus Biosciences Inc (CHRS) estimates and forecasts
This year revenue growth is estimated to fall -79.01% from the last financial year’s standing.
3 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.12M for the same. And 4 analysts are in estimates of company making revenue of 14.79M in the next quarter. Company posted 64.98M and 70.77M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -27.36% during past 5 years.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
Insiders are in possession of 6.54% of company’s total shares while institution are holding 57.84 percent of that, with stock having share float percentage of 61.88%. Investors also watch the number of corporate investors in a company very closely, which is 57.84% institutions for Coherus Biosciences Inc that are currently holding shares of the company. BLACKROCK INC. is the top institutional holder at CHRS for having 11.75 million shares of worth $20.33 million. And as of 2024-06-30, it was holding 10.2356 of the company’s outstanding shares.
The second largest institutional holder is VANGUARD GROUP INC, which was holding about 10.6 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.2339 of outstanding shares, having a total worth of $18.34 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 3.43 shares of worth $2.71 million or 2.96% of the total outstanding shares. The later fund manager was in possession of 2.9 shares on Mar 31, 2025 , making its stake of worth around $2.29 million in the company or a holder of 2.50% of company’s stock.
